

YZATIS - Evaluation et évolution de la prise en charge thérapeutique à moyen terme des patients séropositifs pour le VIH-1 traités avec une combinaison antirétrovirale incluant Atazanavir

Head :Bennai Yacia, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Last update : 09/05/2017 | Version : 1 | ID : 128

General

Identification

Detailed name Evaluation et évolution de la prise en charge thérapeutique à moyen terme des patients séropositifs pour le VIH-1 traités avec une combinaison antirétrovirale incluant Atazanavir

Sign or acronym YZATIS

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL n°04-1334 (18/10/2004)

General Aspects

Medical area Infectious diseases

Others (details) HIV

Keywords care, Atazanavir

Scientific investigator(s) (Contact)

Name of the director Bennai
Surname Yacia
Address 3, rue J. Monier - 92500 Rueil Malmaison
Phone +33 (0)1 58 83 60 00
Email yacia.bennai@bms.com
Unit Bristol-Myers Squibb

Name of the director Schmidely

Surname	Nathalie
Address	3, rue J. Monier - 92500 Rueil Malmaison
Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb

Collaborations

Funding

Funding status	Private
----------------	---------

Details	Bristol-Myers Squibb
---------	----------------------

Governance of the database

Sponsor(s) or organisation(s) responsible	Bristol-Myers Squibb France (BMS)
Organisation status	Private

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Longitudinal study (except cohorts)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	random sampling in clusters

Database objective

Main objective	Describe the arrangements for caring for patients treated by a combination of treatments including
----------------	--

ATAZANAVIR according to the grounds for introducing the treatment (virological failure of the previous treatment or other)

Inclusion criteria

M or F, aged 18 years or older, seropositive for HIV-1, treated via a combination of ARV treatments including ATV for which the main reason for introduction of the current treatment was: - virological failure of the previous treatment OR - another reason.

Population type

Age

Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered

Sick population

Gender

Male
Woman

Geography area

National

Detail of the geography area

National representativeness

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)

2004

Date of last collection (YYYY or MM/YYYY)

2006

Size of the database

Size of the database (number of individuals)

[500-1000[individuals

Details of the number of individuals

626

Data

Database activity

Data collection completed

Type of data collected

Clinical data
Declarative data
Biological data

Clinical data (detail)	Direct physical measures Medical registration
Declarative data (detail)	Paper self-questionnaire
Biological data (detail)	cholesterol, TG, glycemia, bilirubin, liver enzymes, VL & CD4 (if available)
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health care consumption and services Quality of life/health perception
Care consumption (detail)	Medicines consumption

Procedures

Data collection method	Specific observation notebooks
Participant monitoring	Yes
Details on monitoring of participants	M3, M6, M12
Links to administrative sources	No

Promotion and access

Promotion

Access

Terms of data access (charter for data provision, format of data, availability delay)	publication
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only